Faeth Therapeutics and Veru posted double-digit stock gains on the same Monday, for reasons that had nothing to do with each other. Faeth used its quarterly numbers to show it is sitting on nine times the cash it had six months ago. Veru used its own earnings call to confirm a trial enrolled faster than planned. Neither company announced a drug that works. Both moved the stock anyway.
Faeth Therapeutics Jumps 18% as Cash Position Grows Nearly Ninefold to $186 Million
Faeth Therapeutics (Nasdaq: FTH) shares rose about 18% on August 10, with investors zeroing in on its PIKTOR pipeline update days after the company reported second-quarter results and presented new translational data at a cancer conference. Cash, cash equivalents, and marketable securities stood at $186.4 million at quarter’s end, up from $21.2 million at the end of 2025.
That jump traces back to February, when Faeth merged into what was then Sensei Biotherapeutics through an all-stock deal paired with a $200 million private placement. The combined company took the Faeth name in June and now trades under the ticker FTH.
PIKTOR pairs serabelisib, a PI3K-alpha inhibitor, with sapanisertib, which blocks two other nodes in the same cancer-signaling pathway. The Phase 2 trial testing the combination in second-line advanced endometrial cancer remains on track for topline data by year-end. A second study in HR-positive, HER2-negative breast cancer dosed its first patient in April, with initial data expected in 2027.
Faeth’s market cap now sits around $600 million, built almost entirely on a trial that has not reported results yet.
Veru Gains 17% After Obesity Trial Tops Its Enrollment Target
Veru (Nasdaq: VERU) shares climbed 17% on August 10. The trigger was enrollment, not data. The company’s Phase 2b PLATEAU trial, testing enobosarm alongside semaglutide in obese patients 65 and older, finished enrolling 239 patients against an original target of 200.
Enobosarm is designed to help preserve muscle and bone while patients lose fat on a GLP-1 drug, addressing a known side effect of rapid weight loss on Wegovy-type medications. Veru already has a supply agreement with Novo Nordisk to support the trial, and the U.S. Patent Office issued a notice of allowance this month for a patent covering the enobosarm-semaglutide combination through October 2044.
The company posted a $7 million net loss for its fiscal third quarter, narrower than the $7.3 million loss a year earlier. According to Veru, interim results from PLATEAU are expected in the first quarter of 2027, with final topline data due at the end of that year.
That leaves a long wait. Nothing about full enrollment guarantees the drug combination actually works.
FTH, VERU: Forward-Looking FAQ
It matters for survival, not for the stock reaction. The $186 million gives Faeth runway regardless of the endometrial cancer outcome, but a negative Phase 2 readout would still hit the shares hard since PIKTOR is effectively the company’s only near-term catalyst.
No. Enrollment completion only starts the clock. The first data readout is interim results in Q1 2027, roughly five months away, with final topline data not expected until Q4 2027.
Sources
- RTTNews: Faeth Therapeutics Gains 18% As PIKTOR Approaches Phase 2 Endometrial Cancer Data, August 10, 2026
- BusinessWire / BioSpace: Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates, August 4, 2026
- BioSpace: Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection at Upcoming Scientific Conference, August 2026
- RTTNews: Veru Gains 17% As Obesity Trial Exceeds Enrollment Target, Data Due In Q1, 2027, August 10, 2026
- BioSpace / GlobeNewswire: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress, August 10, 2026
Editorial Disclosure
This roundup is based entirely on publicly available information including named wire service releases, company press releases, and financial news reporting. Securities and entities discussed include Faeth Therapeutics, Inc. (Nasdaq: FTH) and Veru Inc. (Nasdaq: VERU). aktiego.com has not received any compensation from any company, IR firm, or third party mentioned. No staff member or principal of aktiego.com holds a position in any security mentioned at the time of publication. Faeth Therapeutics’ cash position and PIKTOR pipeline details are sourced to its August 4, 2026 press release and its presentation at the STOP Cancer conference; the August 10, 2026 stock move is sourced to contemporaneous financial reporting. Faeth’s Phase 2 endometrial cancer topline data has not yet been reported as of publication, and the company’s market capitalization of approximately $600 million is cited here as a factual data point only. Veru’s enrollment figures, financial results, and patent status are sourced to its August 10, 2026 press release. Interim and final data from the Phase 2b PLATEAU trial have not yet been reported as of publication; the trial’s completion of enrollment is not evidence that the drug combination is effective. Both companies discussed are clinical-stage or late clinical-stage with no FDA-approved products for the indications named in this article; their ability to reach further milestones depends on continued access to capital and future clinical results. Small cap and micro-cap stocks listed on the CSE, TSX, TSXV, and Nasdaq are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
